{"brief_title": "Phase I/II Study of Curdlan Sulfate", "brief_summary": "To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.", "detailed_description": "In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested. In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Curdlan sulfate", "criteria": "Inclusion Criteria Patients must have: - HIV seropositivity. - No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or other malignancy. - CD4 count < 500 cells/mm3. - No critical illness that would shorten life expectancy to < 16 weeks. Exclusion Criteria Concurrent Medication: Excluded: - Antiretroviral or other experimental therapies. - Anticoagulants. - Steroids. - Cytotoxic or immunosuppressive agents. Concurrent Treatment: Excluded: - Radiotherapy. Patients with the following prior condition are excluded: History of heparin sensitivity. Prior Medication: Excluded within 1 month prior to study entry: - Antiretroviral or other experimental therapies. - Anticoagulants. - Steroids. - Cytotoxic or immunosuppressive agents. Prior Treatment: Excluded: - Radiotherapy within 1 month prior to study entry. Active IV drug abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "60 Years", "healthy_volunteers": "No", "id": "NCT00002100.xml"}